Molecular mechanisms of regulation of CYP enzymes of phase I metabolism of xenobiotics - synthetic drugs and herbal preparations

• Autorzy: Bogacz A. , Karasiewicz M. , Kujawski R. , Bartkowiak-Wieczorek J. , Cichocka J. , Kowalska A. , Czerny B. , Rudzinska K. , Grzeskowiak E. , Mrozikiewicz P. M.

Warianty tytułu

PL

Molekularne mechanizmy regulacji enzymów CYP i fazy metabolizmu ksenobiotyków - leków sysntetycznych i preparatów roślinnych

• Języki publikacji: EN

Abstrakty

EN

The understanding of the pharmacokinetic properties of synthetic drugs as well as herbal preparations used in treatment of many diseases offers a real opportunity to eliminate or minimize the interaction between the active substances. This is of particular clinical importance because it can decrease or increase the action of drugs what is the major cause of failure of pharmacotherapy. Understanding the molecular basis of interaction of substances with enzymes of drug metabolism is extremely helpful in treatment planning and its practical application. The experimental and clinical studies aimed to complete the characterization of the mechanisms of many factors that modulate the activity of cytochrome P450 enzymes, can provide a lot of evidence guaranteeing the safety of herbal products.

PL

Zrozumienie właściwości farmakokinetycznych leków syntetycznych, jak również preparatów roślinnych stosowanych w leczeniu wielu schorzeń stwarza realną szansę na eliminację lub zminimalizowanie interakcji pomiędzy substancjami aktywnymi. Ma to szczególne znaczenie kliniczne, ponieważ może prowadzić do osłabienia bądź nasilenia działania leków znajdujących się u podłoża niepowodzeń farmakoterapii. Poznanie podłoża molekularnego interakcji substancji z enzymami metabolizmu leków jest niezwykle pomocne podczas planowania terapii i jej praktycznego zastosowania. Wiele dowodów gwarantujących bezpieczeństwo stosowania produktów zielarskich mogą dostarczyć badania eksperymentalne oraz kliniczne zmierzające do pełnej charakterystyki mechanizmów działania wielu czynników modulujących aktywność enzymów cytochromu P450.

Słowa kluczowe

EN

molecular mechanism; regulation mechanism; cytochrome P450; metabolism phase; xenobiotic; synthetic drug; herbal preparation; herbal product

• Wydawca: -
• Czasopismo: Herba Polonica
• Rocznik: 2012
• Tom: 58
• Numer: 3
• Opis fizyczny: p.46-59,ref.

Twórcy

autor

Bogacz A.

• Quality Control of Medicinal Products and Dietary Supplements Department, Insitute of Natural Fibres and Medicinal Plants, Libelta 27, 61-707 Poznan, Poland

autor

Karasiewicz M.

autor

Kujawski R.

autor

Bartkowiak-Wieczorek J.

autor

Cichocka J.

autor

Kowalska A.

autor

Czerny B.

autor

Rudzinska K.

autor

Grzeskowiak E.

autor

Mrozikiewicz P. M.

Bibliografia

• 1. Tamasi V. In vivo and in vitro induction of P450 enzymes in regenerating liver cells. PHD School of Pharmaceutical Sciences 2004; 1-14.
• 2. Hrycay EG, Bandiera SM. Cytochrome P450 Enzymes. In: Gad SC (ed.). Preclinical development handbook: ADME and Biopharmaceutical Properties. New York 2008:627-696.
• 3. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82:667-715.
• 4. Maciejewska M, Bogacz A, Mrozikiewicz PM. Zmiany aktywności wybranych enzymów z rodziny cytochromu P-450 w wyniku interakcji leku roślinnego z lekiem syntetycznym. Herba Pol 2008; 54:57-67.
• 5. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 1998; 8:227-238.
• 6. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Raultalahti M, Haukka J, Impivaara O, et al. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behavior. Pharmacogenetics 2000; 10:5-10.
• 7. Vesell ES. The liver. Biology and pathobiology. Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA (eds.). Pharmacogenetics 1988; 213-234.
• 8. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14:121-141.
• 9. Whitlock JP. Induction of cytochrome P4501A1. Ann Rev Pharmacol Toxicol 1999; 39:103-125.
• 10. Waxman DJ. P450 gene regulation by structurally diverse xenochemicals: central role of nuclearreceptors CAR, PXR and PPAR. Arch Biochem Biophys 1999; 369:11-23.
• 11. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347:321-337.
• 12. Hankinson D. The aryl hydrocarbon receptor comlex. Annu Rev Pharmcol Toxicol 1995; 35:307-340.
• 13. Gu YZ, Hogenesh JB, Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000; 40:519-561.
• 14. Hoffman EC, Reyes H, Chu F-F, Bander F, Conley LH, Brooks BA et al. Cloning of a factor required for activity of the Ah (Dioxin) receptor. Science 1991; 252:954-958.
• 15. Mimura J, Yamashita K, Nakamura K, Morita M, Takagi TN, Nakao K et al. Loss of teratogenic response to 2,3,7,8-tetrachlordibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 1997; 2:645-654.
• 16. Bertilsson G, Heidrich J, Svensson K, Äsman M, Jendeberg L, Sydow-Bäckman M et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998; 95:12208-12213.
• 17. Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Meter CM, Ong ES et al. SXR, novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998; 12:3195-3205.
• 18. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-1023.
• 19. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000; 275:15122-27.
• 20. Pichard-Garcia L, Pascussi JM, Maurel P. Carotenoids activate PXR and are inducers of CYP2B6 and CYP3A4 in human hepatocytes in primary culture. In: 13th International Symposium on Microsomes andDrug Oxidations. 2000; 195.
• 21. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al. St. John’s wort induceshepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97:7500-7502.
• 22. Savas U, Griffin KJ, Johnson EF. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: an expanded role for nuclear hormone receptors. Mol Pharmacol 1999; 56:851-857.
• 23. Pacussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptorand retionoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by preganane X receptor activators. Mol Pharmacol 2000; 58:361-372.
• 24. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochrome P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41:1047-1055.
• 25. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406:435-439.
• 26. Fisher S, Beuers U, Spengler U, Zwiebel FM, Koebe HG. Hepatic levels of bile acids in end –stage chronic cholestatic liver disease. Clin Chim Acta 1996; 251:173-186.
• 27. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999; 274: 6043-6046.
• 28. Tzameli I, Pissios P, Schuetz EG, Moore DD. The xenobiotic compound 1,4-bis[2-(3,5-dichoropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 2000; 20:2951-2958.
• 29. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L et al. Cytokines down-regulate expression of ajor cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44:707-715.
• 30. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducibleexpression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; 22:1143-1153.
• 31. Forman BM, Tzameli I, Choi HS, Chen J, Simha D, Seol W et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-β. Nature 1998; 395:612-615.
• 32. Honkakoski P, Zelko I, Sueyoshi T, Negishi M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the Phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 1998; 18:5652-5658.
• 33. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 2003; 278:17277-83.
• 34. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 1999; 19:6318-6322.
• 35. Negishi M. Nuclear receptor CAR as a phenobarbital induction signal of CYP2B genes. In: 13th International Symposium on Microsomes and Drug Oxidations. 2000; 56.
• 36. Ibeanu GC, Goldstein JA. Transcriptional regulation of human CYP2C genes: functional compa rison ofCYP2C9 and CYP2C18 promoter regions. Biochemistry 1995; 34:8028-8036.
• 37. Chung I, Bresnick E. Regulation of the constitutive expression of the human CYP1A2 gene: Cis elements and their interactions with proteins. Mol Pharmacol 1995; 47:677-685.
• 38. Liu SY, Gonzalez FJ. Role of the liver-enriched transcription factor HNF-1 alpha in expression of the CYP2E1 gene. DNA Cell Biol 1995; 14:285-293.
• 39. Song BJ. Gene structure and multiple regulations of the ethanol-inducible cytochrome P4502E1 (CYP2E1) subfamily. In: Watson RR, ed. Drug and Alcohol Abuse Reviews. Totowa NJ. Humana Press, 1995; 6:177-192.
• 40. Cairns W, Smith ChAD, McLaren AW, Wolf CR. Characterization of the Human Cytochrome P4502D6 Promoter. J Biol Chem 1996; 271:25269-25276.
• 41. Venepally P, Chen O, Kemper B. Transcriptional regulatory elements for basal expression of cytochrome 450IIC genes. J Biol Chem 1992; 267:17333-17338.
• 42. Sladek FM, Zhong WM, Lai E, Darnell JE. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 1990; 4:2353-2365.
• 43. Enmark E, Gustatsson JA. Orphan nuclear receptors – the eight years. Mol Endocrinol 1996; 10:1293- 1307.